By Anthony O. Goriainoff
AstraZeneca and Daiichi Sankyo said that datopotamab deruxtecan, a cancer drug, combined with the Imfinzi cancer treatment--with or without chemotherapy--showed disease control rates of 92% and 93% respectively in patients with previously untreated advanced or metastatic non-small cell lung cancer.
The Anglo-Swedish pharma giant said Monday that the results reinforced its confidence in this being a potential treatment option for patients with this type of lung cancer.
"Three ongoing pivotal trials are evaluating datopotamab deruxtecan and immune checkpoint inhibitor combinations in first-line advanced non-small cell lung cancer," AstraZeneca said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
09-11-23 0240ET